secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2026-06-01T20:01:27+00:00
Accession:  0001213900-26-063481
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030
--------------------------------------------------------------------------------

- Oruka amended IL-23 license with Paragon to expand field to include inflammatory bowel disease (IBD).
- Cannot dose ORKA-001 in combination IBD trial before June 1, 2028, or monotherapy before June 1, 2030.
- If material transaction occurs (e.g., change of control), monotherapy restriction ends June 1, 2028.
- Paragon's exclusivity for monospecific antibodies in IBD extended to October 11, 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/0001213900-26-063481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-063481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer